TY - JOUR
A2 - Kahaleh, Michel
AU - Lu, Wenxia
AU - Li, Sainan
AU - Li, Jingjing
AU - Wang, Jianrong
AU - Zhang, Rong
AU - Zhou, Yuqing
AU - Yin, Qin
AU - Zheng, Yuanyuan
AU - Wang, Fan
AU - Xia, Yujing
AU - Chen, Kan
AU - Liu, Tong
AU - Lu, Jie
AU - Zhou, Yingqun
AU - Guo, Chuanyong
PY - 2016
DA - 2016/08/29
TI - Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis
SP - 1459790
VL - 2016
AB - A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). Methods. MEDLINE/PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Science Citation Index (ISI Web of Science), Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI) were searched for relevant randomized controlled trials on the effects of n-3 polyunsaturated fatty acids (PUFAs) in patients with NAFLD from inception to May 2015. Ten studies were included in this meta-analysis. Results. 577 cases of NAFLD/NASH in ten randomized controlled trials (RCTs) were included. The results of the meta-analysis showed that benefit changes in liver fat favored PUFA treatment, and it was also beneficial for GGT, but it was not significant on ALT, AST, TC, and LDL. Conclusions. In this meta-analysis, omega-3 PUFAs improved liver fat, GGT, TG, and HDL in patients with NAFLD/NASH. Therefore, n-3 PUFAs may be a new treatment option for NAFLD.
SN - 1687-6121
UR - https://doi.org/10.1155/2016/1459790
DO - 10.1155/2016/1459790
JF - Gastroenterology Research and Practice
PB - Hindawi Publishing Corporation
KW -
ER -